Bringing Retinal Health into focus

Gene Therapy for Degenerative Retinal Diseases

Lead Program

ELOVL2 Gene Therapy for Dry AMD »

Visgenx is developing therapeutics based on increasing expression of a gene known as ELOVL2 which has been shown to regulate aging in the retina and other tissues.

Dry-AMD Overview

Dry-AMD is a
progressive disease

Resulting in loss of photoreceptor cells and visual acuity

Patients struggle with everyday tasks

Such as driving, cooking, reading, and facial recognition

11 million people are affected in the US

There are no approved therapies


Age-Related Macular Degeneration and Geographic Atrophy»

We believe dysregulation of lipid (fatty acid) bio-synthesis resulting from declining expression of a gene known as ELOVL2 underlies Dry Macular Degeneration.

Our Science »

Innovation in Focus.

We are scientists, entrepreneurs and drug developers with a goal to develop ELOVL2 based therapeutics to slow or halt aging-related disorders.

Our Team »

Visgenx in Focus.

Our goal is to develop therapeutics that slow or halt cellular senescense in macular degeneration and other age-related disorders by “turning back the clock” to a more youthful level of ELOVL2 expression.

Contact us »